Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01582945 · ClinicalTrials.gov registry record · NA
Ketamine Infusion for Treatment-resistant Major Depressive Disorder
A NA study, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- NA
- Development phase
- 14
- Enrollment target
NCT01582945: Completed NA study, sponsored by Massachusetts General Hospital.
NCT01582945 is a NA study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 14 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01582945, a NA study, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- NA
- Development phase
- 14 participants
- Enrollment target
Study Summary
Ketamine infusion has been shown to have rapid antidepressant properties, however the possible use of ketamine in treatment-resistant depression as augmentation has not been investigated. The overall aim of this study is to assess the feasibility, safety and tolerability, efficacy and duration of the effect of intravenous N-methyl-D-aspartate antagonist ketamine as augmentation of antidepressants for chronic suicidal ideation in subjects with severe treatment-resistant depression (TRD). This is an open-label study (pilot).
Interventions
- DRUG Ketamine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2012-04 |
| Est. Completion | 2014-12 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01582945
The ClinicalTrials.gov registry entry for NCT01582945 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Ketamine is the first listed.
NCT01582945 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01582945 about?
NCT01582945 is a clinical study titled "Ketamine Infusion for Treatment-resistant Major Depressive Disorder". Ketamine infusion has been shown to have rapid antidepressant properties, however the possible use of ketamine in treatment-resistant depression as augmentation has not been investigated. The overall aim of this study is to assess the feasibility, safety and tolerability, efficacy and duration of th...
What is the current status of trial NCT01582945?
This trial is currently completed. It is a NA study. The enrollment target is 14 participants. The study started on 2012-04. Estimated completion is 2014-12.
What interventions are being tested in trial NCT01582945?
The interventions under investigation include: Ketamine (DRUG).
Who is sponsoring clinical trial NCT01582945?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.